Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up.

Agarwal S, Hartz AM, Elmquist WF, Bauer B.

Curr Pharm Des. 2011;17(26):2793-802. Review.

2.

Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.

Kodaira H, Kusuhara H, Ushiki J, Fuse E, Sugiyama Y.

J Pharmacol Exp Ther. 2010 Jun;333(3):788-96. doi: 10.1124/jpet.109.162321. Epub 2010 Mar 19.

4.

Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier.

Poller B, Drewe J, Krähenbühl S, Huwyler J, Gutmann H.

Cell Mol Neurobiol. 2010 Jan;30(1):63-70. doi: 10.1007/s10571-009-9431-1. Epub 2009 Jul 23.

PMID:
19629677
5.

Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line.

Zrieki A, Farinotti R, Buyse M.

Pharm Res. 2008 Sep;25(9):1991-2001. doi: 10.1007/s11095-008-9596-1. Epub 2008 Jun 26.

PMID:
18581209
6.

A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.

Graber-Maier A, Gutmann H, Drewe J.

Mol Pharm. 2010 Oct 4;7(5):1618-28. doi: 10.1021/mp100040f. Epub 2010 Aug 11.

PMID:
20701289
7.

Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma.

Becker CM, Oberoi RK, McFarren SJ, Muldoon DM, Pafundi DH, Pokorny JL, Brinkmann DH, Ohlfest JR, Sarkaria JN, Largaespada DA, Elmquist WF.

Neuro Oncol. 2015 Sep;17(9):1210-9. doi: 10.1093/neuonc/nov081. Epub 2015 May 12.

8.

ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS.

Daood M, Tsai C, Ahdab-Barmada M, Watchko JF.

Neuropediatrics. 2008 Aug;39(4):211-8. doi: 10.1055/s-0028-1103272. Epub 2009 Jan 22.

9.

Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.

Lee YJ, Kusuhara H, Jonker JW, Schinkel AH, Sugiyama Y.

J Pharmacol Exp Ther. 2005 Jan;312(1):44-52. Epub 2004 Sep 24.

10.

Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model.

Parrish KE, Pokorny J, Mittapalli RK, Bakken K, Sarkaria JN, Elmquist WF.

J Pharmacol Exp Ther. 2015 Nov;355(2):264-71. doi: 10.1124/jpet.115.228213. Epub 2015 Sep 9.

11.

Regulation of ABC transporters blood-brain barrier: the good, the bad, and the ugly.

Miller DS.

Adv Cancer Res. 2015;125:43-70. doi: 10.1016/bs.acr.2014.10.002. Epub 2015 Jan 8. Review.

PMID:
25640266
12.

(R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.

Römermann K, Wanek T, Bankstahl M, Bankstahl JP, Fedrowitz M, Müller M, Löscher W, Kuntner C, Langer O.

Nucl Med Biol. 2013 Oct;40(7):873-8. doi: 10.1016/j.nucmedbio.2013.05.012. Epub 2013 Jul 8.

13.

Evaluation of drug efflux transporter liabilities of darifenacin in cell culture models of the blood-brain and blood-ocular barriers.

Miller DW, Hinton M, Chen F.

Neurourol Urodyn. 2011 Nov;30(8):1633-8. doi: 10.1002/nau.21110. Epub 2011 Aug 8.

PMID:
21826715
14.

Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein.

Fujita Y, Noguchi K, Suzuki T, Katayama K, Sugimoto Y.

BMC Res Notes. 2013 Nov 6;6:445. doi: 10.1186/1756-0500-6-445.

15.

Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells.

Hirayama C, Watanabe H, Nakashima R, Nanbu T, Hamada A, Kuniyasu A, Nakayama H, Kawaguchi T, Saito H.

Pharm Res. 2008 Apr;25(4):827-35. Epub 2007 Oct 13.

PMID:
17934801
16.

Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening.

Tournier N, Valette H, Peyronneau MA, Saba W, Goutal S, Kuhnast B, Dollé F, Scherrmann JM, Cisternino S, Bottlaender M.

J Nucl Med. 2011 Mar;52(3):415-23. doi: 10.2967/jnumed.110.079608. Epub 2011 Feb 14.

17.

Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.

Sane R, Agarwal S, Mittapalli RK, Elmquist WF.

J Pharmacol Exp Ther. 2013 Apr;345(1):111-24. doi: 10.1124/jpet.112.199786. Epub 2013 Feb 8.

18.

Induction of P-glycoprotein and Bcrp at the rat blood-brain barrier following a subchronic morphine treatment is mediated through NMDA/COX-2 activation.

Yousif S, Chaves C, Potin S, Margaill I, Scherrmann JM, Declèves X.

J Neurochem. 2012 Nov;123(4):491-503. doi: 10.1111/j.1471-4159.2012.07890.x. Epub 2012 Sep 3.

19.

ATP-binding cassette transporters in primary central nervous system lymphoma: decreased expression of MDR1 P-glycoprotein and breast cancer resistance protein in tumor capillary endothelial cells.

Sakata S, Fujiwara M, Ohtsuka K, Kamma H, Nagane M, Sakamoto A, Fujioka Y.

Oncol Rep. 2011 Feb;25(2):333-9. doi: 10.3892/or.2010.1102. Epub 2010 Dec 13.

PMID:
21165575
20.

Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.

Minocha M, Khurana V, Qin B, Pal D, Mitra AK.

Int J Pharm. 2012 Sep 15;434(1-2):306-14. doi: 10.1016/j.ijpharm.2012.05.028. Epub 2012 May 23.

Supplemental Content

Support Center